知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.023 秒)

    Process for typing of HCV isolates
    2.
    发明申请
    Process for typing of HCV isolates 失效
    HCV分离株的分型方法

    公开(公告)号：US20040191768A1

    公开(公告)日：2004-09-30

    申请号：US10822711

    申请日：2004-04-13

    申请人： INNOGENETICS, S.A.

    发明人： Geert Maertens ,  Lieven Stuyver ,  Rudi Rossau ,  Hugo Van Heuverswyn

    IPC分类号： C12Q001/70

    CPC分类号： C12Q1/707 ,  C12Q1/6834 ,  C12Q2563/131 ,  C12Q2545/101 ,  C12Q2525/101 ,  C12Q2531/113

    摘要： The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position null291 to nucleotide at position null66 of the 5null untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be identified.

    摘要翻译： 本发明涉及用于对先前鉴定为HCV阳性的生物样品中存在的任何HCV分离物进行基因分型的方法，以及根据与其它HCV分离株的同源性百分比对所述分离物进行分类的方法，包括以下步骤： 如果需要的话，核糖核苷酸或脱氧核糖核苷酸可以在合适的变性下与至少一个约10至约40个核苷酸的探针接触，所述探针易于与位置延伸的结构域延伸的区域杂交。 291到由其cDNA序列表示的HCV分离物之一的5'非翻译区的-66位的核苷酸，其中所述编号的位置开始于编码HCV多蛋白的开放阅读框的第一个ATG密码子，或与所述探针 与上述定义的探针互补，检测可能形成在所述探针与H的核苷酸序列之间的复合物 CV分离鉴定。

    Process for typing HCV isolates
    4.
    发明申请
    Process for typing HCV isolates 失效
    分离HCV分离株的方法

    公开(公告)号：US20030036053A1

    公开(公告)日：2003-02-20

    申请号：US09899044

    申请日：2001-07-06

    申请人： Innogenetics N.V.

    发明人： Geert Maertens ,  Lieven Stuyver ,  Rudi Rossau ,  Hugo Van Heuverswyn

    IPC分类号： C12Q001/70 ,  C12Q001/68

    CPC分类号： C12Q1/707 ,  C12Q1/6834 ,  C12Q2563/131 ,  C12Q2545/101 ,  C12Q2525/101 ,  C12Q2531/113

    摘要： The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position null291 to nucleotide at position null66 of the 5null untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be identified.

    摘要翻译： 本发明涉及用于对先前鉴定为HCV阳性的生物样品中存在的任何HCV分离物进行基因分型的方法，以及根据与其它HCV分离株的同源性百分比对所述分离物进行分类的方法，包括以下步骤： 如果需要的话，核糖核苷酸或脱氧核糖核苷酸可以在合适的变性下与至少一个约10至约40个核苷酸的探针接触，所述探针易于与位置延伸的结构域延伸的区域杂交。 291到由其cDNA序列表示的HCV分离物之一的5'非翻译区的-66位的核苷酸，其中所述编号的位置开始于编码HCV多蛋白的开放阅读框的第一个ATG密码子，或与所述探针 与上述定义的探针互补，检测可能形成在所述探针与H的核苷酸序列之间的复合物 CV分离鉴定。

    Process for typing of HCV isolates
    5.
    发明申请
    Process for typing of HCV isolates 失效

    公开(公告)号：US20020168626A1

    公开(公告)日：2002-11-14

    申请号：US09899302

    申请日：2001-07-06

    申请人： Innogenetics N.V.

    发明人： Geert Maertens ,  Lieven Stuyver ,  Rudi Rossau ,  Hugo Van Heuverswyn

    IPC分类号： C12Q001/70 ,  C12Q001/68 ,  C07H021/04

    CPC分类号： C12Q1/707 ,  C12Q1/6834 ,  C12Q2563/131 ,  C12Q2545/101 ,  C12Q2525/101 ,  C12Q2531/113

    摘要： The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position null291 to nucleotide at position null66 of the 5null untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be identified.

    Redox reversible HCV proteins with native-like conformation
    6.
    发明申请
    Redox reversible HCV proteins with native-like conformation 审中-公开
    氧化还原可逆性HCV蛋白与天然样构象

    公开(公告)号：US20040185061A1

    公开(公告)日：2004-09-23

    申请号：US10825219

    申请日：2004-04-16

    申请人： Innogenetics N.V.

    发明人： Alfons Bosman ,  Erik Depla ,  Geert Maertens

    IPC分类号： C12Q001/70 ,  A61K039/29 ,  C07K014/02

    CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K16/109 ,  C12N2770/24222

    摘要： The present invention relates to HCV proteins in which cysteine residues are reversibly protected during purification. Eventually, this purification procedure results in HCV proteins with biological activity and a native-like protein conformation, which present corresponding epitopes. The present invention pertains also to drug screening methods using these HCV proteins, and diagnostic and therapeutic applications, such as vaccines and drugs.

    摘要翻译： 本发明涉及其中半胱氨酸残基在纯化期间被可逆保护的HCV蛋白质。 最终，该纯化程序导致具有生物活性的HCV蛋白质和呈现相应表位的天然样蛋白质构象。 本发明还涉及使用这些HCV蛋白质的药物筛选方法，以及诊断和治疗应用，例如疫苗和药物。

    Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
    8.
    发明申请
    Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents 有权
    丙型肝炎病毒基因型的序列及其作为治疗和诊断剂的用途

    公开(公告)号：US20030064360A1

    公开(公告)日：2003-04-03

    申请号：US09873224

    申请日：2001-06-05

    申请人： N.V. INNOGENETICS S.A.

    发明人： Geert Maertens ,  Lieven Stuyver

    IPC分类号： C12Q001/70 ,  C07H021/04 ,  C12N007/00 ,  C12P021/02 ,  C12N005/06 ,  C12N015/86

    CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C12N2770/24222

    摘要： The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3: and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spacing positions 8023 to 8235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.

    摘要翻译： 本发明涉及包含至少一种含有8个或更多个连续核苷酸的多核苷酸的多核酸组合物，其对应于来自HCV 3型核心/ E1区域的位置417至957的区域的核苷酸序列; 和/或跨越HCV 3型NS3区域的位置4664至4730的区域和/或跨越HCV 3型NS3 / 4区域的位置4892至5292的区域; 和/或HCV3型BR36亚组的NS5区域的区域间隔位置8023至8235; 和/或从核心区域的核苷酸379开始的HCV型4a的编码区; 和/或HCV 4型的编码区; 和/或HCV 5型的编码区，其中所述核苷酸编号相对于表1所示的HCV核酸的编号，并且所述多核苷酸与已知的HCV I型具有至少一个核苷酸差异，和/ 或上述区域中的HCV 2型HCV基因组，或其补体。

    Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
    9.
    发明申请
    Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents 失效
    丙型肝炎病毒基因型的序列及其作为预防，治疗和诊断剂的用途

    公开(公告)号：US20020183508A1

    公开(公告)日：2002-12-05

    申请号：US09851138

    申请日：2001-05-09

    申请人： Innogenetics N.V.

    发明人： Geert Maertens ,  Lieven Stuyver

    IPC分类号： C12Q001/70 ,  C07H021/04 ,  C12N007/00

    CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/525 ,  C12N2770/24222

    摘要： The present invention relates to new genomic nucleotide sequences and amino acid sequences corresponding to the coding region of these genomes. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes. More particularly, the present invention relates to new HCV type 7 sequences, new HCV type 9 sequences, new HCV type 10 and new HCV type 11 sequences. Also, the present invention relates to new HCV type 1 sequences of subtypes 1d, 1e, 1f and 1g; new HCV type 2 sequences of subtypes 2e, 2f, 2g, 2h, 2I, 2k and 2l; new HCV type 3 sequences of subtype 3g, new HCV type 4 sequences of subtypes 4k, 4l and 4m; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the Core, the E1 and the NS5 regions of new HCV types 7, 9, 10 and 11, as well as of new variants (subtypes) of HCV types 1, 2, 3 and 4. These new HCV sequences are useful to diagnose the presence of HCV type 1, and/or type 2, and/or type 3, and/or type 4, and/or type 7, and/or 9, and/or type 10, and/or type 11 genotypes or serotypes in a biological sample. Moreover, the availability of these new type-specific sequences can increase the overall sensitivity of HCV detection and should also prove to be useful for prophylactic and therapeutic purposes.

    摘要翻译： 本发明涉及对应于这些基因组的编码区的新的基因组核苷酸序列和氨基酸序列。 本发明涉及不同于已知HCV类型和亚型的新HCV类型和亚型序列。 更具体地，本发明涉及新的HCV 7型序列，新型HCV 9型序列，新型HCV 10型和新型HCV 11型序列。 此外，本发明涉及新型的1型，1e型，1型和1型的HCV型1型序列; 亚型2e，2f，2g，2h，2I，2k和21l的新HCV 2型序列; 亚型3g的新HCV 3型序列，亚型4k，4l和4m的新型HCV 4型序列; 它们的制备过程及其在诊断，预防和治疗中的应用。 更具体地，本发明提供新型HCV 7型，9型，10型和11型的核心，E1和NS5区域的新型特异性序列，以及HCV类型1,2和2的新变体（亚型） 这些新的HCV序列可用于诊断HCV 1型和/或2型和/或3型和/或4型和/或7型和/或9型和/ 或10型，和/或11型基因型或血清型。 此外，这些新型特异性序列的可用性可以增加HCV检测的总体灵敏度，并且还应证明可用于预防和治疗目的。

    Process for typing of HCV isolates
    10.
    发明申请
    Process for typing of HCV isolates 失效
    HCV分离株的分型方法

    公开(公告)号：US20020106638A1

    公开(公告)日：2002-08-08

    申请号：US09899082

    申请日：2001-07-06

    申请人： Innogenetics N.V.

    发明人： Geert Maertens ,  Lieven Stuyver ,  Rudi Rossau ,  Hugo Van Heuverswyn

    IPC分类号： C12Q001/70 ,  C12Q001/68

    CPC分类号： C12Q1/707 ,  C12Q1/6834 ,  C12Q2563/131 ,  C12Q2545/101 ,  C12Q2525/101 ,  C12Q2531/113

    摘要： The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position null291 to nucleotide at position null66 of the 5null untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be identified.

    摘要翻译： 本发明涉及用于对先前鉴定为HCV阳性的生物样品中存在的任何HCV分离物进行基因分型的方法，以及根据与其它HCV分离株的同源性百分比对所述分离物进行分类的方法，包括以下步骤： 如果需要的话，核糖核苷酸或脱氧核糖核苷酸可以在合适的变性下与至少一个约10至约40个核苷酸的探针接触，所述探针易于与位置延伸的结构域延伸的区域杂交。 291到由其cDNA序列表示的HCV分离物之一的5'非翻译区的-66位的核苷酸，其中所述编号的位置开始于编码HCV多蛋白的开放阅读框的第一个ATG密码子，或与所述探针 与上述定义的探针互补，检测可能形成在所述探针与H的核苷酸序列之间的复合物 CV分离鉴定。